About

Bio-Neuroscience convenes an outstanding mix of innovators, CEOs and decision-makers in CNS neuroscience drug development from the leading biotech companies, investors and pharma companies in the sector

Insight - Access - Engagement - Impact

Profy Countdown Timer: Visible on Live site

Premier Gathering of Innovators

The one event which convenes a high-level, by-invitation, boutique gathering of thought leaders, innovators, CEOs and senior decision-makers from the leading stakeholders groups in CNS neuroscience drug development.

The business of CNS Neuroscience drug development.

Where CEOs and C-level executives of the hottest companies come together with industry leaders, decision-makers, patient organizations, funders and the leading investors in CNS neuroscience drug development to dive into the the issues that matter most to stakeholders.

Elevating Engagement and Collaboration

A unique level of sustained high-quality discussion, access, engagement and partnering in a truly curated summit unlike other events.

Broadreach Summits - What Participants Say

A masterfully organized holistic view of developments in policy, clinical and business strategy, patient care and investment.

Pawel Swieboda

Director General

A masterfully organized holistic view of developments in policy, clinical and business strategy, patient care and investment.

Pawel Swieboda

Director General

Vision

Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.

Drive transformational connections, discussion and partnering for startups and growth companies.

Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.

Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.

Get feedback and advice on your business, your objectives and your core challenges from leading innovators, investors and industry leaders in CNS neuroscience drug development.

Why Now?

Now is the time for CNS neuroscience drug development. We have entered a time when truly rational drug discovery and development is possible and where new discoveries, tools, technologies, biomarkers and insights enable improved development.

Investor and industry interest is booming, yet key challenges remain that can only be addressed by bringing together the leading translational research, clinicians, entrepreneurs, CEOs, CSOs and CMOs from the leading biotech companies, with relevant therapeutic area and business development heads from big pharma and large biotech, as well as the Partners and Directors heading neuroscience investment at the most active and important investment funds.

The 2024 pilot edition established Bio-Neuroscience as a unique, high-level and interactive summit providing participants exceptional value in terms of the experience, insight, access and impact.

shutterstock_128316104 Thinking Impulses copy.jpg

Meet the Advisory Board

Advisory Board

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Joachim Scholpp

Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim

Sourav Kole

Managing Director - Dolby Family Ventures

Rita Balice-Gordon

Chief Executive Officer - Muna Therapeutics

Martien Kas

President - European College of NeuroPsychopharmacology (ECNP)

Kalpana Merchant

Member of the Board - Envisagenics, President & CEO - Transthera, Adjunct Prof. Northwestern University Feinberg School of Medicine

Kees Been

Chief Executive Officer - Kynexis Therapeutics Inc.

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Juan Carlos Lopez

Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Andrea Soto Padilla

Business Development - Amsterdam UMC

Mark Treherne

Chairperson - Monument Therapeutics, Commercial Scientists, Investor, Chair of Talisman Therapeutics, Ubiquent, NuVision Biotherapies

Advisory Board

Meet the Speakers - Check back for regular updates and additions.

Proudly convening leading speakers and stakeholders from across the sector

Steve Brannan

FIRESIDE CHAT - Former Chief Medical Officer - Karuna Therapeutics

Jan Klatt

Senior Vice President, Head of the Development Unit Neurology & Immunology - Merck KGaA

Hugh Nuthall

Executive Director, Search & Evaluation, Neuroscience - Eli Lilly

Nawal Roy

Founder & CEO - Holmusk

Leonard van den Berg

Chair - TRICALS, Founder & Chair - ENCALS, Founder & Director - ALS Centrum Nederland

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Frédéric Destébecq

Executive Director - European Brain Council (EBC) & European Brain Foundation (EBF)

Steven Biesmans

Principal - UCB Ventures

Sunitha Malepati

Founder - Buffalo Initiative, Vice President - CACNA1A Foundation

Robert Thorne

KEYNOTE SPEAKER - Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)

Claire Leurent

Managing Director - AbbVie Ventures

Raúl Martín-Ruiz

Partner - Ysios Capital

Klaus Dugi

CEO - Vandria SA

Alexander Natz

Secretary General - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Husseini K Manji, MD, FRCPC

KEYNOTE SPEAKER - Professor - Oxford University, Co-chair - UK Government Mental Health Mission

Allyson Berent

Chief Scientific Officer - Foundation for Angelman Syndrome Therapeutics (FAST)

Thomas Michael Thestrup

Senior Principal - Angelini Ventures

Stevin Zorn

President & CEO - MindImmune Therapeutics

Bruce Leuchter

President & CEO - Neurvati Neurosciences

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Clara Campàs

Managing Partner & Co-Founder - Asabys Partners

Brigit de Jong

Neurologist - Amsterdam University Medical Center

Vikas Sharma

Chief Business Officer - QurAlis

Present

Presenting Companies

Benefit From

Pre-summit guidance and feedback on your deck.

A pre-summit dry-run presentation with feedback.

5 minute presentation followed by 5 minutes Q&A with an expert panel of relevant investors and industry: In the plenary session.

Join a curated selection of the most innovative, promising and high potential companies with potential to transform CNS neuroscience drug development & treatment. Selection is by excellence and potential, not by price tag! There is no cost to present beyond the regular startup or private company registration fees.

Your Poster in the networking area.

Meeting space in the main networking area to facilitate additional post presentation discussion in the 45 minute networking break immediately following your presentation session.

2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience drug development.

Option to add an exclusive company exhibition stand. There is no requirement to sponsor or exhibit; these exist as separate options each with their own unique range of benefits, however these will not have any impact on the selection of presenting companies.

Apply or Nominate to Pitch

Who's Coming

Two days of sustained, interactive discussion, networking and partnering with:

Industry Leaders

Industry decison-makers, Heads of Therapeutic Area, Scouting, Alliance Management, Business Development & Licensing, Strategy & Portfolio from pharma & large biotech.

Key Opinion Leaders

Key Opinion Leaders from research, clinical development & care, strategy, finance, business development, licensing, regulatory, market launch & M&A.

Founders & CEOs

Founders, CEOs & C-Level from the most innovative and hottest CNS neuroscience companies leading innovation & deals in the sector.

Government & NGOs

Public funding bodies, policy makers, public agencies, societies, associations & NGOs in neuroscience, agencies, regulatory bodies.

Investors

Managing Partners & Partners from the most active CNS Neuroscience investing VC funds, Managing Directors & Directors of the leading Corporate Venture, Private Equity and Family Office Funds, Foundations & more.

Patients

A selected group of leading patient driven companies, non profits, foundations, associations and charities focused on the development of novel therapies for patients.

Venue

Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in CNS Neuroscience drug development.

Hotel Jakarta
Javakade 766, 1019 SH Amsterdam,
Netherlands

Bio-Neuroscience takes place at Hotel Jakarta, a sustainable modern hotel designed as a green oasis on the IJ river. The selection of the Hotel Jakarta Amsterdam as the new venue was made based on its central location, comfortable rooms and green atmosphere, and a setup which is well suited for the highly interactive but boutique interactive nature of Bio-Neuroscience, including improved plenary spaces, natural light, and increased networking space for business development and networking.